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Objective: This study used a decision-analytic framework to assess the cost-effectiveness of
brexpiprazole vs comparator branded therapies for reducing relapses and hospitalizations among
adults with schizophrenia from a US payer perspective.
Methods: An economic model was developed to assess patients with stable schizophrenia
initiating treatment with brexpiprazole (1–4 mg), cariprazine (1–6 mg), or lurasidone (40–80
mg) over a 1-year period. After 6 months, patients remained on treatment or discontinued due
to relapse, adverse events, or other reasons. Patients who discontinued due to relapse or adverse
events were assumed to have switched to other therapy, and those who discontinued due to
other reasons were assumed to have received no therapy. Primary outcomes were incremental
cost per relapse avoided and hospitalization avoided, and the secondary outcome was cost per
quality-adjusted life-year (QALY) gained. Sensitivity and scenario analyses were also conducted.
Results: Brexpiprazole was associated with the highest per-patient clinical effectiveness
(avoided relapses 0.637, avoided hospitalizations 0.719, QALYs 0.707) among comparators,
followed by cariprazine (avoided relapses 0.590, avoided hospitalizations 0.683, QALYs 0.683)
and lurasidone (avoided relapses 0.400, avoided hospitalizations 0.536, QALYs 0.623). Annual
per-patient health-care costs were lowest for brexpiprazole ($20,510), followed by cariprazine
($22,282) and lurasidone ($25,510). Brexpiprazole was the least costly and most effective
treatment strategy for all outcomes. Results were sensitive to relapse rates and daily cost of
brexpiprazole. Limitations include data principally obtained from drug-specific randomized
withdrawal studies and lack of direct-comparison trials.
Conclusion: This analysis evaluated brexpiprazole treatment for the reduction of schizophrenia
relapses and hospitalizations over a 1-year period compared to other recently available branded
antipsychotics, and excluded generic antipsychotic treatments. Brexpiprazole treatment may
lead to clinical benefits and medical cost savings, and provides a cost-effective treatment option
for patients relatively to other branded second-generation antipsychotics.
Keywords: schizophrenia, cost-effectiveness, relapse prevention, cost-benefit, indirect analysis,
event avoided, hospitalization avoided, brexpiprazole
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Schizophrenia is a complex and disabling mental disorder characterized by delusions,
hallucinations, disorganized speech and behavior, negative symptoms, cognitive
impairment, and other symptoms that contribute to social and occupational dysfunction.1 The disorder affects approximately 1.1% of adults in the USA.2 The economic
burden of schizophrenia in the US is substantial: estimated at $156 billion in 2013.3
Schizophrenia-relapse rates are high, and further contribute to the economic burden
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of the disorder. Acher-Svanum et al found that total annual
direct mental health-care costs were about three times higher
among persons with schizophrenia who experienced relapses
in the 6 months prior to the study compared to patients who
did not experience relapses in that period.4
The goals of schizophrenia treatment have evolved over
the last several decades, and focus on increasing quality of
life (QoL) and functioning and striving for remission.5–7
Guidelines recommend psychosocial interventions incorporated into all phases of patient management, with the goal of
minimizing stress and maximizing patient functioning.6 The
American Psychiatric Association practice guidelines support the use of programs, such as community interventions
(eg, Program for Assertive Community Treatment, family
interventions, supported employment, cognitive behavioral
therapy, social skills training, and programs of early intervention to delay relapse).6 The association recommends
antipsychotic agents as the mainstay of treatment for schizophrenia; however, variance in pharmacological profiles create
clinically relevant variability in tolerability and efficacy.8
Typical antipsychotics (ie, first-generation antipsychotics) are
antagonists at dopamine D2 receptors and effective against
psychotic symptoms. However, these agents have a high rate
of motoric adverse events (AEs), such as drug-induced parkinsonism and tardive dyskinesia, at therapeutic doses. Atypical antipsychotic agents (ie, second-generation antipsychotics
[SGAs]) available in the US include clozapine, risperidone,
olanzapine, quetiapine, ziprasidone, aripiprazole, lurasidone,
paliperidone, iloperidone, cariprazine, and asenapine. These
atypical antipsychotics differ from one another in their tolerability profile. Although atypical antipsychotics may have
reduced risk of motoric side effects, there is evidence that
demonstrates variable risk of weight gain, diabetes, hyperlipidemia, and cardiovascular complications.
Although antipsychotic medications can manage the
symptoms of schizophrenia effectively and help patients to
achieve remission, relapses are common.9 In addition, discontinuation rates for antipsychotic medications are high in
both clinical trial and real-world settings. For example, in the
US Clinical Antipsychotic Trials of Intervention Effectiveness study,10 the overall discontinuation rate over 18 months
for patients with chronic schizophrenia taking antipsychotics was 74%, and in a 3-year European observational study
discontinuation rates were 34%–66%.11
Poor tolerability and side effects of antipsychotics are
among the primary reasons for premature treatment discontinuation, resulting in inadequate symptom resolution and
an increased risk of relapse.12,13 Therefore, additional toler-
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able treatment options are needed. Brexpiprazole is an SGA
approved by the US Food and Drug Administration (FDA)
in July 2015 as monotherapy for schizophrenia in adults. The
efficacy of brexpiprazole in schizophrenia was demonstrated
in two 6-week, randomized, double-blind, placebo-controlled,
fixed-dose clinical trials.14,15 Brexpiprazole has demonstrated
a low incidence of sedating or activating AEs, a low rate of
long-term metabolic effects, and moderate weight gain.14–16
The efficacy of brexpiprazole was also demonstrated in a
randomized-withdrawal, double-blind, placebo-controlled,
52-week maintenance study,17 which showed a reduction in
risk of relapse of 71% vs placebo over 1 year and an incidence
of AEs that was comparable to placebo.
Evidence of efficacy and tolerability remains important
in the evaluation and comparison of available therapies; however, it is also important to determine their cost-effectiveness,
given limitations on health-care spending. In the absence of
head-to-head studies, indirect comparisons to evaluate the
cost-effectiveness of treatments for schizophrenia can assist
in health-care decision-making. This study used a decisionanalytic framework to assess the cost-effectiveness of brexpiprazole in schizophrenia for reducing relapses and hospitalizations
among adults with schizophrenia from a US payer perspective.
Evaluating the cost-effectiveness of newly available
branded treatments in schizophrenia can shape policies
concerning treatment coverage and reimbursement. Decision
makers emphasize the need for more timely information.18
In the US, the majority of oral antipsychotics are available
as generic products. Given increasing pressures to manage
health-care costs, it is expected that generic-drug utilization
is generally prioritized over the use of branded treatments.
For policy makers evaluating new branded treatments for
formulary placement, an appropriate pharmacoeconomic
analysis would involve comparisons of newly available and
existing branded treatments.

Methods
Model overview
A decision-analytic model was developed to evaluate a hypothetical cohort of adult patients with stable schizophrenia
initiating treatment with brexpiprazole, cariprazine, or lurasidone. Lurasidone and cariprazine were selected as comparators because they are the most recently FDA-approved SGAs
and long-term prevention studies on them were comparable
to those on brexpiprazole in terms of patient population,
trial design, and end points. In the long-term maintenance
trials, all patients were stabilized before entering a randomized, double-blind phase for at least 12 weeks. Additionally,
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relapse definitions were comparable across trials. Modeled
treatment doses were based on those evaluated in long-term
prevention studies from which clinical events were derived:
brexpiprazole (1–4 mg), cariprazine (1–6 mg), and lurasidone
(40–80 mg). It was assumed that patients remained adherent
to treatment during treatment-initiation and -switch periods.
Model outputs are reported over a 1-year model time
horizon, which was chosen to be consistent with the clinical
trial duration period. It is clinically relevant to model schizophrenia outcomes within 1 year, because clinical effectiveness
and treatment discontinuation are typically seen within this
period and data beyond 1 year are limited.10,19 Due to the
length of the time horizon, discounting (ie, translating future
costs and benefits into present-day values) was not applied.
The model incorporated direct costs related to drug
acquisition, AE treatment, relapse-related treatment, and
patient monitoring. All costs are reported in 2016 US$.
Clinical events were estimated from long-term relapse trials
(efficacy) and acute trials (AEs) for each model comparator. Cost-effectiveness was evaluated for primary outcomes
of incremental cost per relapse avoided and cost per hospitalization avoided and the secondary outcome of cost per
quality-adjusted life-year (QALY) gained. The model was
programmed using Microsoft Excel 2010.

Model population and structure
The model evaluated a hypothetical cohort of adults with
stable-p hase schizophrenia consistently with patients
enrolled in long-term prevention studies of brexpiprazole,17
cariprazine,20 and lurasidone.21 Initially, patients entered the
model and were treated with brexpiprazole, cariprazine, or

lurasidone (Figure 1). Following treatment initiation, patients
remained on therapy for the full year or discontinued treatment after 6 months due to relapse/lack of treatment efficacy, AEs, or other reasons (including cost of medication,
nonadherence, patient preference, or unknown). Because the
median time to discontinuation in the brexpiprazole study17
was 169 days, the use of 6 months (approximately 183 days)
was unlikely to bias model results.
Patients who discontinued due to relapse/lack of treatment efficacy or AEs were assumed to switch to composite
therapy, which included generic SGAs (ie, olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole). Patients
who discontinued due to other reasons were assumed to
receive no additional therapy. For patients who switched
to composite therapy, it was assumed that the likelihood of
receiving any one of the therapies was the same. Therefore,
rates of relapse and AEs were calculated as averages for
the composite therapies. Although patients who switched
to composite therapy could experience relapse or AEs,
they were assumed to continue treatment throughout the
remainder of the year.

Model estimation
Clinical inputs

Key clinical inputs were derived from 52-week maintenance relapse studies for brexpiprazole17 and cariprazine,20
a 28-week maintenance relapse study for lurasidone,21 and
published reports and package inserts (PIs) for SGAs used for
composite therapy. Clinical parameters included in the model
were rates of treatment discontinuation, relapse/impending
relapse, and AEs (Tables 1–3).

Continue treatment

Relapse

Continue therapy

No relapse
b

Relapse

Composite therapy

Discontinued due to relapse/lack of efficacy
Treatmenta
Patients with schizophrenia
at stable phase

No relapse
Relapse

b

Discontinued due to AEs

Composite therapy

Discontinued due to other reasons

No therapy

No relapse
Relapse
No relapse

Before discontinuation: 6 months

After discontinuation: 6 months
1-year time horizon

Figure 1 Model structure.
Notes: aTreatment included brexpiprazole, lurasidone, and cariprazine; bComposite therapy: olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole
Abbreviation: AEs, adverse events.
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In the absence of direct-comparison trials of treatments, an
indirect comparison was conducted to determine differences
in treatment discontinuation and relapse. Because treatments
were all compared to placebo in their long-term maintenance
trials, this indirect comparison used placebo as the common
Table 1 Probability of treatment discontinuation and relapse at
6 months
Mean

SEa

Source

Probability of treatment discontinuation at 6 months due to
relapse
Brexpiprazole
16.0%
0.8%
Fleischhacker et al17
Lurasidone
30.9%
1.5%
Tandon et al21
Cariprazine
18.5%
0.9%
Durgam et al20
Probability of treatment discontinuation at 6 months due to
AEs
Brexpiprazole
23.3%
1.2%
Fleischhacker et al17
Lurasidone
7.8%
0.4%
Tandon et al21
Cariprazine
8.2%
0.4%
Durgam et al20
Probability of treatment discontinuation at 6 months due to
other reasonsb
Brexpiprazole
16.5%
0.8%
Fleischhacker et al17
Lurasidone
32.0%
1.6%
Tandon et al21
Cariprazine
18.8%
0.9%
Durgam et al20
Probability of relapse in composite arm
Composite therapy
14.9%b
NA
Calculation
Olanzapine
4.0%
0.2%
Beasley et al43
Risperidone
15.0%
0.8%
Csernansky et al39
Quetiapine
15.4%
0.8%
Peuskens et al44
Ziprasidone
16.3%
0.8%
Arato et al45
Aripiprazole
23.7%
1.2%
Pigott et al46

comparator to obtain model-efficacy values. Derived rates
were calculated for treatment discontinuation, which allowed
a more accurate comparison of clinical events across comparator cohorts. In general, derived rates were calculated as the
product between the relative clinical rate within a trial (active
vs respective placebo) and a pooled placebo clinical rate (see
Supplementary material for calculation details). The probabilities of relapse at 6 months for treatments in composite therapy
are presented in Table 1. Because relapses vary in severity, the
model assumed that 77.3% of relapses resulted in an inpatient
hospitalization and 22.7% were treated on an outpatient basis.22

Adverse events
The model assumed that patients could experience six types
of potential treatment-emergent AEs: akathisia, extrapyramidal symptoms, glucose abnormalities (fasting glucose criteria), lipid abnormalities (fasting total cholesterol criteria),
sedation, and weight gain (≥7% weight gain from baseline;
Table 2). AE rates were pooled as needed,23 and absolute
rates of AEs across comparator trials were used.24,25 AE rates
for composite-therapy treatments were obtained from the
product labels. Sedation as a unique AE identifier was not
reported in the lurasidone PI; therefore, a weighted average
was calculated using published data.26

Economic inputs

Notes: aAll SEs assumed to be 5% of the mean; bother reasons included cost of
medication, nonadherence, patient preference, or unknown.
Abbreviation: NA, not applicable.

Cost parameters were derived from the literature, and
included schizophrenia-care costs related to drug acquisition, relapse, treatment discontinuation/switching, and

Table 2 Adverse-event rates
Treatment

Akathisia,
mean (SE)

EPS,
mean (SE)

Glucose
abnormalities,a
mean (SE)

Lipid
abnormalities,b
mean (SE)

Sedation,
mean (SE)

Weight
gain ≥7%,
mean (SE)

Source

Brexpiprazole
Lurasidone

6.9% (0.3%)
11.5% (0.6%)

14.0% (0.7%)
11.5% (0.6%)

3.4% (0.2%)
9.6% (0.5%)

2.3% (0.1%)
5.7% (0.3%)

2.7% (0.1%)
10.0% (0.5%)

10.2% (0.5%)
4.8%(0.2%)

Cariprazine

11.0% (0.6%)

16.0%c (0.8%)

8.4% (0.4%)

3.4%d (0.2%)

4.0% (0.2%)

3.0% (0.2%)

Composite
therapy
Olanzapine
Risperidone
Quetiapine
Ziprasidone
Aripiprazole

7.2% (0.4%)

14.0% (0.7%)

5.3% (0.3%)

6.4% (0.3%)

15.4% (0.8%)

14.8% (0.7%)

8.7%
10.0%
1.2%
8.0%
8.0%

24.2%
15.1%f
3.5%g
14.0%
13.0%

2.2%
0.3%
2.4%
17.6%
3.8%

2.8%
4.6%
18.0%
3.9%
2.5%

29.9%e
8.2%
18.0%e
14.0%e
7.0%h

22.2%
10.8%
23.0%
9.7%
8.1%

Rexulti PI24
Latuda PI25
Citrome26
Vraylar summary review47
Durgam et al48
Calculation (mean rate
across SGAs)
Zyprexa PI49
Risperdal PI50
Seroquel PI51
Geodon PI52
Abilify PI53

Notes: Absolute rates (not placebo-adjusted). aFasting glucose criteria: normal to high (<100–≥126 mg/dL). For lurasidone, the normal to high criterion was ≥160 mg/dL;
for risperidone, the normal–high cutoff was <140 mg/dL to ≥200 mg/dL. bFasting total cholesterol criteria: normal–high (<200–≥240 mg/dL). For lurasidone, the normal–high
criterion was ≤200 mg/dL; for quetiapine, the criterion was ≥240 mg/dL. cAny EPS, excluding akathisia/restlessness. dWeighted average calculated based on total cholesterol
(>1.3 × ULN [200 mg/dL]) rates from three treatment arms: 1.5, 3, and 4.5 mg. eNo sedation data reported. Somnolence rate was used. fNo EPS data reported. Parkinsonism
(includes extrapyramidal disorder, musculoskeletal stiffness, parkinsonism, cogwheel rigidity, akinesia, bradykinesia, hypokinesia) rate from two treatment arms: 2–8 mg and
>8–16 mg/day. gIncludes restless and extrapyramidal disorder. hData from pooled incidence (rounded) of adverse reactions that occurred during acute therapy (up to 6 weeks
in schizophrenia and up to 3 weeks in bipolar mania).
Abbreviations: EPS, extrapyramidal symptoms; PI, package insert; SGAs, second-generation antipsychotics; ULN, upper limit of normal.
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Table 3 Estimated cost inputs
Treatment-related costs
Monitoring
Treatment switch
Relapse-treatment costs
Inpatient
Outpatient
Adverse events
Akathisia
EPS
Glucose abnormalities
Lipid abnormalities
Sedation
Weight gain ≥7%
Treatment-acquisition costs (WAC)
Brexpiprazole
4 mg ($/day)
Lurasidone
40 mg ($/day)
60 mg ($/day)
80 mg ($/day)
Cariprazine
1.5 mg ($/day)
3.0 mg ($/day)
4.5 mg ($/day)
6.0 mg ($/day)
Composite therapy
Olanzapine
10 mg ($/day)
Risperidone
4 mg ($/day)
Quetiapine
200/300 mg ($/day)
Ziprasidone
40/60 mg ($/day)
Aripiprazole
30 mg ($/day)

Estimate

SE

Source

$95.19
$282.98

$4.76
$14.15

US Bureau of Labor Statistics27
Citrome et al19

$32,495.41
$657.69

$1,624.77
$32.88

Agency for Healthcare Research and Quality54
Park and Kuntz55

$232.94
$242.01
$75.65
$173.39
$282.98
$830.19

$11.65
$12.10
$3.78
$8.67
$14.15
$41.51

Citrome et al19
US Bureau of Labor Statistics27

$31.16

$1.56

Truven Health Analytics56

$30.73
$30.73
$30.73

$1.54
$1.54
$1.54

$33.54
$33.54
$33.54
$33.54

$1.68
$1.68
$1.68
$1.68

$18.44

$0.92

$23.81

$1.19

$18.75

$0.94

$16.24

$0.81

$42.05

$2.10

Notes: All costs reported in 2016 US$.
Abbreviations: EPS, extrapyramidal symptoms; WAC, wholesale-acquisition cost.

treatment costs for AEs (Table 3). Costs are reported as 2016
US$, and where applicable are inflated to 2016 US$ using
the medical care component of the consumer price index.27
The model also included the cost of treatment-related
monitoring, considered the office-visit cost of monitoring
per outpatient,27 and assumed that a treated patient would
require one monitoring visit per month. An additional cost
of switching treatments was also applied. 19,27 If patients
discontinued treatment due to other reasons, the analysis
did not assign any composite therapy, and thus no additional
treatment-related costs applied. Lastly, the costs of treating
relevant AEs (Table 3) were assumed to occur only within
a 6-week period.

ClinicoEconomics and Outcomes Research 2018:10

Utility inputs
The model used health-state utilities to estimate the impact
of treatments on patients’ QoL. Utility weights were obtained
from published QoL data among patients with stable schizophrenia.28,29 Utilities associated with relapse with or without
hospitalization and AEs were derived from the utility value
from stable schizophrenia. Mean (SE) health-state-utility
values were 0.88 (4.4%) for stable disease, 0.53 (2.7%) for
relapse with hospitalization, and 0.74 (3.7%) for relapse
without hospitalization.28,29 Mean (SE) utility decrements
associated with AEs were 0.090 (0.005) for akathisia,28 0.099
(0.005) for extrapyramidal symptoms,28 0.067 (0.003) for glucose abnormalities,30 0.099 (0.005) for lipid abnormalities,31
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0.084 (0.004) for sedation,32 and 0.036 (0.002) for weight gain
≥7%.32 Because utility-weight decrements were not available for glucose abnormalities, the utility for symptomatic
nonsevere hypoglycemia in patients with diabetes was used.

Total direct schizophrenia-related health-care costs, incremental costs, and clinical improvement (ie, number of
relapses and hospitalizations avoided) were estimated for
each treatment in the model. Incremental cost:effectiveness
ratios (ICERs) were expressed as cost per relapse avoided,
cost per hospitalization avoided, and cost per QALY gained.
These outcomes were calculated at the end of 1 year as the
ratio of the difference between the cost of schizophreniarelated care in patients receiving brexpiprazole vs alternative
treatment and the difference in the number of patients avoiding relapses or hospitalizations, respectively.

The PSA was repeated 1,000 times, and results reporting
the NMB for different willingness-to-pay (WTP) thresholds ($0–$100,000) per selected outcome (avoided relapse,
avoided hospitalization, and QALYs) were used to evaluate
the robustness of model outcomes.
Scenario analyses were conducted to understand further
the impact of model estimate assumptions for AEs and drug
costs related to generic options in composite therapy. AE
rates were incorporated into the model using absolute estimates from comparator trials. To assess the impact of using
derived rates of AEs in the model, a scenario analysis was
conducted. Wholesale-acquisition-cost branded pricing was
used to estimate drug costs for treatments in the compositetherapy arm. However, given that treatments are generic, a
second-scenario analysis using retail pricing from national
wholesaler Costco33 was deemed appropriate to assess the
impact of lower-cost drug costs.

Sensitivity analyses

Results

One-way sensitivity analyses were conducted to quantify the
impact of change in individual model parameters on model
outcomes. All clinical and economic parameters were varied
by 1 SD within a predefined statistical distribution of the
base-case values to determine which variables would have
the greatest impact on the incremental net monetary benefit
(NMB).
To assess uncertainty in the cost-effectiveness analysis, a
probabilistic sensitivity analysis (PSA) was also conducted
using a second-order Monte Carlo simulation. The PSA
was performed by simultaneously drawing from appropriate
distribution functions for all model parameters according
to their means and SEs (Tables 1–3). All rates were varied
using β-distribution and costs varied using γ-distribution.

In a hypothetical cohort of 1,000 patients, the model estimated that brexpiprazole was the dominant treatment strategy
compared to cariprazine and lurasidone over the 1-year time
horizon (Table 4). In terms of clinical outcomes, treatment
with brexpiprazole was associated with higher effectiveness
(all outcomes shown per patient; avoided relapses 0.637,
avoided hospitalizations 0.719, QALYs 0.707), followed by
cariprazine (avoided relapses 0.590, avoided hospitalizations
0.683, QALYs 0.683) and lurasidone (avoided relapses 0.400,
avoided hospitalizations 0.536, QALYs 0.623). Brexpiprazole was also associated with lower total schizophreniarelated health-care costs per patient ($20,510), followed by
cariprazine ($22,282) and lurasidone ($25,510). In the ICE
analyses, brexpiprazole was the dominant (ie, less costly and

Analysis

Table 4 Base-case cost-effectiveness analysis
Total annual cost per patient
(medical + pharmacy)
Relapses
Relapses avoided
Hospitalizations
Hospitalizations avoided
QALYs
Change in total cost
Change in avoided relapses
Change in hospitalizations avoided
Change in QALYs
ICER per avoided relapse
ICER per hospitalization avoided
ICER per QALY

Brexpiprazole

Lurasidone

Cariprazine

$20,510

$25,510

$22,283

0.363
0.637
0.281
0.719
0.707
-$1,772
0.047
0.036
0.025
Dominant
Dominant
Dominant

0.600
0.400
0.464
0.536
0.623
$3,227
–0.191
–0.147
–0.060
Dominated
Dominated
Dominated

0.410
0.590
0.317
0.683
0.683
Reference
Reference
Reference
Reference
Reference
Reference
Reference

Abbreviations: ICER, incremental cost:effectiveness ratio; QALY, quality-adjusted life-year.
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more effective) treatment strategy compared with lurasidone
and cariprazine for all ICERs (Table 4). A cost-effectiveness
plane displaying results is presented in Figure 2.
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Sensitivity analyses
Figures S1 and S2 show the results of the one-way sensitivity
analyses comparing brexpiprazole vs lurasidone and cariprazine, respectively, for the ten most influential variables at
a WTP threshold of $30,000 per relapse avoided. As shown
in the tornado diagram, when brexpiprazole was compared
to lurasidone (Figure S1), the model parameters with the
largest impact on the incremental NMB were the 6-month
discontinuation probability due to relapse for brexpiprazole, 6-month discontinuation probability due to relapse
for lurasidone, and daily cost of brexpiprazole. Results of
one-way sensitivity analyses with the same WTP ($30,000)
per relapse-related hospitalization avoided and QALYs
showed similar results. When brexpiprazole was compared
to cariprazine (Figure S2), the results were consistent with
the comparison of brexpiprazole and lurasidone. Results of
the PSA using a WTP range of $0–$100,000 per avoided
relapse, per avoided hospitalization, and per QALY are
shown in Table S1. Based on 1,000 simulations, all results
indicated that brexpiprazole was associated with lower cost
and better effectiveness, yielding the highest NMB among
all comparators.

Scenario analysis
Calculated derived rates of AEs from the first-scenario analysis are presented in Table S2. In this scenario, brexpiprazole
was also the dominant treatment strategy compared with
lurasidone and cariprazine for all ICERs evaluated (Table S3).
In the second-scenario analysis using retail pricing from
Costco33 for the composite treatments, cost-effectiveness
results were similar to the base-case analysis (Table S4). For
each treatment, the total annual cost per patient was slightly
lower compared to results reported in the base-case scenario.
Results from these two scenario analyses showed consistent
findings with the base-case analyses.

Discussion
Schizophrenia poses substantial human and economic burden, and despite the availability of several SGAs, it remains
a difficult disorder to treat effectively. A recent study34 found
that schizophrenia was one of the three most burdensome
diseases on an annual per patient basis, estimated at $46,537
in 2014 US$. Relapses have a significant impact on the
economic burden of schizophrenia, with relapsed patients
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incurring three to four times higher health-care costs than
nonrelapsed patients, driven primarily by the costs of hospitalization for relapsed patients.4,35
Brexpiprazole is a recently approved SGA treatment option
for adults with schizophrenia. To our knowledge, this is the
first cost-effectiveness analysis to compare brexpiprazole with
other branded SGAs in reducing schizophrenia relapses and
hospitalizations. Results of the base-case cost-effectiveness
analyses showed that brexpiprazole was the dominant treatment strategy compared with lurasidone and cariprazine for all
outcomes assessed. Although this is the only cost-effectiveness
analysis of brexpiprazole compared to lurasidone and cariprazine we are aware of, the cost-effectiveness of lurasidone has
been explored in previous s tudies;36–38 however, these models
included different populations, comparators, inputs, assumptions, and time horizons, making comparison across studies
difficult. Model results should be considered in light of limitations. The analysis was based on data from placebo-controlled
trials; as such, results of this analysis may not be generalizable
to treatment provided under real-world conditions. In addition,
the probability of relapse for the composite therapy risperidone
was not derived from a randomized, placebo-controlled withdrawal study, as one was not conducted by the manufacturer.
Therefore, probability of relapse came from a maintenance
study of risperidone vs haloperidol that did not involve a period
of stabilization followed by medication withdrawal.39
The use of observed AE rates from short-term acuteschizophrenia trials due to lack of long-term comparable
comparator data could be another study limitation. However,
we employed an indirect-comparison method and derived
placebo-adjusted rates in scenario analyses. Both scenario and
sensitivity analyses suggested that those rates were not identified as major model drivers and had only a minimal impact on
the cost-effectiveness results. Furthermore, incorporation of
the short-term cost of treating AEs, such as change in glucose,
cholesterol, and weight only reflects short-term treatment
costs; however, the potential long-term risks of diabetes,
obesity, and complications, such as cerebrovascular accident
and cardiovascular disease, are not included in the analysis
and warrant consideration in a longer-term evaluation.
The model included only the treatment doses that were
evaluated in the long-term prevention trials; therefore, efficacy at higher doses for lurasidone was not evaluated and
may affect findings. In the long-term, placebo-controlled
maintenance trial of lurasidone, patients were randomized to
40–80 mg/day lurasidone or placebo.21 However, the PI for
lurasidone recommends a dose of up to 160 mg per day,25 and
some patients who have an inadequate response to doses up to
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Figure 2 Cost-effectiveness plane per patient.
Notes: (A) Cost-effectiveness per relapse avoided; (B) cost-effectiveness per hospitalization avoided; (C) cost-effectiveness per QALY gained.
Abbreviation: QALY, quality-adjusted life-year.
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80 mg/day will require higher-dose treatment.40 As noted by
Citrome,41 the Tandon et al21 study had some different findings
between US and non-US study sites, which may have further
limited the effect size observed in this study relative to other
similar studies of SGAs. Furthermore, given the objective of
the study, this analysis considered only the branded agents
that are available in the US for which a generic formulation
is not available and where supportive long-term prevention
trials have been published.
Finally, this cost-effectiveness analysis takes a US payer
perspective, and thus results may not be generalizable to other
populations and/or countries in which health-care-resource
utilization and clinical practice may be different. This model
also assumed that 77.3% of all relapses resulted in an inpatient hospitalization and the remaining relapses (22.7%) were
treated on an outpatient basis.22 This assumption was based
on a study conducted in England, which may not reflect US
treatment patterns. To account for the impact of various
parameter estimates on the model results, we conducted both
deterministic and probabilistic sensitivity analyses, which
showed consistent results that brexpiprazole dominated
lurasidone and cariprazine. As noted by Meltzer, attention is
essential to important methodological issues in constructing
cost-effectiveness analysis of treatments in schizophrenia.42
There are key issues in developing a cost-effectiveness model
in schizophrenia that includes perspective, benefits, and
future costs. Due to limited available long-term data across
comparators, the current model framework was deemed
appropriate to evaluate short-term relapse outcomes.

Conclusion
These findings suggest that treatment with brexpiprazole may
lead to clinical benefits and medical cost savings. Brexpiprazole treatment resulted in fewer relapses and hospitalizations,
lower total cost of treatment, and higher QoL compared to
cariprazine and lurasidone. Given the heterogeneity of treatment response in schizophrenia, health plans may consider
making multiple treatment options available, and brexpiprazole offers a cost-effective treatment option.
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Table S1 Mean probabilistic sensitivity analysis results
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Outcome: relapses avoided per patient

Brexpiprazole
Cariprazine
Lurasidone

Relapses avoided per
patient

Net monetary
benefit

Rank

$20,457
$22,254
$25,457

0.707
0.683
0.623

$50,283
$46,021
$36,814

1
2
3

Outcome: relapse-related hospitalization avoided per patient

Brexpiprazole

Total annual cost per patient
(medical + pharmacy costs)

Relapse-related
hospitalization avoided
per patient

Net monetary
benefit

Rank

$18,940

0.719

$52,978

1

Cariprazine

$21,200

0.683

$47,143

2

Lurasidone

$23,929

0.536

$29,663

3

Outcome: QALYs per patient

Brexpiprazole

Total annual cost per patient
(medical + pharmacy costs)

QALYs per patient

Net monetary
benefit

Rank

$20,504

0.706

$50,146

1

Cariprazine

$22,311

0.683

$45,894

2

Lurasidone

$25,549

0.623

$36,706

3

Abbreviation: QALY, quality-adjusted life-year.

Table S2 Scenario analysis: derived rates of adverse events
Treatment

Akathisia
mean

EPS
mean

Glucose
abnormalitiesa
mean

Lipid
abnormalitiesb
mean

Sedation
mean

Weight
gain ≥7%
mean

Source

Brexpiprazole
Lurasidone

5.56%
14.24%

11.88%
13.67%

6.82%
7.66%

4.21%
4.55%

11.33%
7.77%

6.63%
3.87%

Cariprazine

10.19%

14.82%c

8.14%

3.85%

3.36%d

7.99%

Composite therapy

7.8%

13.4%

2.7%

4.2%

13.8%

21.2%

Olanzapine
Risperidone
Quetiapine
Ziprasidone
Aripiprazole

4.52%
17.34%
0.79%
5.94%
10.40%

15.19%
18.93%f
4.53%g
17.60%
10.90%

1.70%
1.51%
4.52%
3.01%
2.78%

3.09%
4.50%
7.12%
3.95%
2.37%

10.72%e
23.68%
12.93%e
11.49%e
10.05%h

38.48%
19.33%
22.17%
12.55%
13.30%

Rexulti PI1
Latuda PI2
Citrome 20123
Vraylar Medical
Reviews4
Durgam 20145
Calculation (mean
rate across SGAs)
Zyprexa PI6
Risperdal PI7
Seroquel PI8
Geodon PI9
Abilify PI10

Notes: Rates of adverse events are absolute rates (not placebo-adjusted). aFasting glucose criteria: Normal to high (<100 to >126 mg/dL). For lurasidone, the normal to high
criterion was ≥160 mg/dL; for risperidone, the normal to high cutoff was <140 mg/dL to ≥200 mg/dL. bFasting total cholesterol criteria: Normal to high (<200 mg/dL to ≥240
mg/dL). For lurasidone, the normal to high criterion was <200 mg/dL; for quetiapine, the criterion was ≥240 mg/dL. cAny EPS excluding akathisia/restlessness. dWeighted
average was calculated based on total cholesterol (>1.3 times ULN [200 mg/dL]) rates from 3 treatment arms: 1.5 mg, 3 mg, and 4.5 mg. eNo sedation data were reported.
Somnolence rate was used. fNo EPS data were reported. Parkinsonism (includes extrapyramidal disorder, musculoskeletal stiffness, parkinsonism, cogwheel rigidity, akinesia,
bradykinesia, hypokinesia) rate from 2 treatment arms: 2–8 mg and >8–16 mg/day. gIncludes restless and extrapyramidal disorder. hData from pooled incidence, rounded to
the nearest percent, of adverse reactions that occurred during acute therapy (up to 6 weeks in schizophrenia and up to 3 weeks in bipolar mania).
Abbreviations: AE, adverse event; EPS, extrapyramidal symptoms; PI, package insert; SGA, second-generation antipsychotic; ULN, upper limit of normal.
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Table S3 Scenario analysis: results of cost-effectiveness analysis using derived AE rates
Total annual cost per patient (medical + pharmacy costs)
Relapses
Avoided relapses
Hospitalizations
Avoided hospitalizations
QALYs
Change in total cost
Change in avoided relapses
Change in avoided hospitalizations
Change in QALYs
ICER per avoided relapse
ICER per avoided hospitalization
ICER per QALY

Brexpiprazole

Lurasidone

Cariprazine

$20,516
0.363
0.637
0.281
0.719
0.698
$1,833
0.047
0.036
0.014
Dominant
Dominant
Dominant

$25,519
0.600
0.400
0.464
0.536
0.624
$3,170
–0.191
–0.147
–0.060
Dominated
Dominated
Dominated

$22,349
0.410
0.590
0.317
0.683
0.684
Reference
Reference
Reference
Reference
Reference
Reference
Reference

Abbreviations: AE, adverse event; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.

Table S4 Scenario analysis: results of cost-effectiveness analysis using generic drug costs for treatments in composite therapy arm
Total annual cost per patient (medical + pharmacy costs)
Relapses
Avoided relapses
Hospitalizations
Avoided hospitalizations
QALYs
Change in total cost
Change in avoided relapses
Change in avoided hospitalizations
Change in QALYs
ICER per avoided relapse
ICER per avoided hospitalization
ICER per QALY

Brexpiprazole

Lurasidone

Cariprazine

$18,931
0.363
0.637
0.281
0.719
0.707
-$2,279
0.0467
0.036
0.0245
Dominant
Dominant
Dominant

$23,955
0.600
0.400
0.464
0.536
0.623
$2,745

$21,210
0.410
0.590
0.317
0.683
0.683
Reference
Reference
Reference
Reference
Reference
Reference
Reference

-0.191
-0.147
-0.060
Dominated
Dominated
Dominated

Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.

Appendix 1
Calculation of treatment discontinuation
relative risks
Treatment discontinuation relative risks were calculated for
active treatment vs placebo using a 3-step method. First,
patients who were terminated by the sponsor were removed
from the efficacy sample, and the discontinuation rate due
to relapse (or due to AE or other reasons) was recalculated
for both the treatment and placebo groups. Of note, in the
maintenance trial of cariprazine, no patients were terminated
by the sponsor; therefore, this step was skipped for the

ClinicoEconomics and Outcomes Research 2018:10

c ariprazine calculation.11 Next, to ensure that all probabilities
were calculated within the same time frame, any transition
probabilities other than 6 months were converted by using
the following formula where EXP refers to the exponential
function and LN refers to the natural logarithm function:
1-EXP(LN(1-Probability)/(Number of weeks in the original
trial/26)). Finally, the 6-month probability from step 2 was
adjusted by applying the relative risk method where the
product between the relative clinical rate within trial (active
vs respective placebo) and a pooled placebo clinical rate
was calculated.
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